Plasma phosphorylated tau species across neurodegenerative and cerebrovascular diseases: An ONDRI study

Elevated plasma phosphorylated tau (p-tau) species are proposed as specific biomarkers of Alzheimer's disease (AD) pathology but have also been reported in amyotrophic lateral sclerosis (ALS). Their profile across neurodegenerative and cerebrovascular diseases, as well as their discriminatory value when combined with other plasma biomarkers, remain uncertain. We studied 551 participants (ages 40.1 to 87.1 years; 207 women), comprising 506 patients from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) multi-site cohort and 45 amyloid-β (Aβ) PET-negative cognitively unimpaired controls from the Brain-Eye Amyloid Memory study. Ten diagnostic groups were studied: mild cognitive impairment (MCI), AD, Parkinson's disease subdivided into cognitively unimpaired (CU), MCI, and dementia, frontotemporal dementia (FTD), cerebrovascular disease (CVD) subdivided into cognitively unimpaired (CU) and cognitively impaired (CI), ALS, and the control group. Baseline visit plasma measurements included p-tau217, p-tau181, Aβ42/40, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). Cross-sectional analyses compared biomarker levels as well as p-tau217-based inference of amyloid positivity status across diagnostic groups. Receiver operating characteristic-area under the curve (ROC-AUC) analyses ascertained the discriminatory capacity of these biomarkers and ratio combinations. Within the ALS group, baseline biomarker measures were also tested for association against baseline clinical features as well as longitudinal measures of neuropsychological change. P-tau217, p-tau181, GFAP, and NfL differed across groups (all P < 0.001). Compared to controls, p-tau217 was elevated in AD and ALS, p-tau181 and GFAP only in AD, and NfL in ALS and FTD. Inferred amyloid-β; positivity was more probable in MCI, AD, ALS, and cognitively impaired CVD groups compared to controls (all P < 0.05). The p-tau217 to NfL ratio discriminated ALS from AD with an ROC-AUC of 0.92 (95% CI 0.85-0.97) compared to p-tau217 alone at 0.65 (95% CI 0.52-0.76). No ALS clinical or longitudinal association survived correction for multiple comparisons. Elevated p-tau217 and inferred amyloid-β; positivity in ALS provide further evidence that the assay signal is not necessarily specific for AD pathology. However, the use of p-tau217 in combination with NfL provides improved discriminatory power between ALS and AD, supporting the use of plasma biomarker combinations rather than sole reliance on individual plasma biomarkers. Inferred amyloid-β; positivity in cognitively impaired CVD may indicate AD and/or cerebral amyloid angiopathy co-pathology. Currently available plasma biomarkers should therefore be used as diagnostic complements and interpreted within clinical context rather than as standalone molecular diagnoses.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-09
DOI
https://doi.org/10.64898/2026.11.06.26367445
Primary Topic
Dementia and Cognitive Impairment Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Plasma phosphorylated tau species across neurodegenerative and cerebrovascular diseases: An ONDRI study

Andrée‐Ann Baril, Anthony Edward Lang, Bruce G. Pollock, Erlan Sanchez et al.
medRxiv
Dementia and Cognitive Impairment Research
preprint

Plasma phosphorylated tau species across neurodegenerative and cerebrovascular diseases: An ONDRI study

Andrée‐Ann Baril, Anthony Edward Lang, Bruce G. Pollock, Erlan Sanchez, Morris Freedman, David F. Tang‐Wai, Dallas Peter Seitz, Ekaterina A. Rogaeva, Stephen Pasternak, Maria Carmela Tartaglia, Andrew Frank, Corinne Eleanor Fischer, Thomas D. L. Steeves, Allison Ann Dilliott, Robert Alexander Hegele, Hlin Kvartsberg, Saira Saeed Mirza, Sandra E. Black, Dar D Dowlatshahi, Lorne H. Zinman, Agessandro Abrahão, David A. Grimes, Sali M.K. Farhan, Douglas P. Munoz, Julia Lee Keith, Rafaella Araujo Gonçalves, Tarek K. Rajji, MICHAEL J. BORRIE, Walter Swardfager, Connie Marras, Sanjeev Kumar, Maurice M. Pasternak, Malcolm A. Binns, Paul Connon, Demetrios J. Sahlas, Mario Masellis, Roger A. Dixon, Michael J. Strong, Henrik Zetterberg, Kübra Tan, Richard H. Swartz, Elizabeth Finger
preprint en

Abstract

Elevated plasma phosphorylated tau (p-tau) species are proposed as specific biomarkers of Alzheimer's disease (AD) pathology but have also been reported in amyotrophic lateral sclerosis (ALS). Their profile across neurodegenerative and cerebrovascular diseases, as well as their discriminatory value when combined with other plasma biomarkers, remain uncertain. We studied 551 participants (ages 40.1 to 87.1 years; 207 women), comprising 506 patients from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) multi-site cohort and 45 amyloid-β (Aβ) PET-negative cognitively unimpaired controls from the Brain-Eye Amyloid Memory study. Ten diagnostic groups were studied: mild cognitive impairment (MCI), AD, Parkinson's disease subdivided into cognitively unimpaired (CU), MCI, and dementia, frontotemporal dementia (FTD), cerebrovascular disease (CVD) subdivided into cognitively unimpaired (CU) and cognitively impaired (CI), ALS, and the control group. Baseline visit plasma measurements included p-tau217, p-tau181, Aβ42/40, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). Cross-sectional analyses compared biomarker levels as well as p-tau217-based inference of amyloid positivity status across diagnostic groups. Receiver operating characteristic-area under the curve (ROC-AUC) analyses ascertained the discriminatory capacity of these biomarkers and ratio combinations. Within the ALS group, baseline biomarker measures were also tested for association against baseline clinical features as well as longitudinal measures of neuropsychological change. P-tau217, p-tau181, GFAP, and NfL differed across groups (all P < 0.001). Compared to controls, p-tau217 was elevated in AD and ALS, p-tau181 and GFAP only in AD, and NfL in ALS and FTD. Inferred amyloid-β; positivity was more probable in MCI, AD, ALS, and cognitively impaired CVD groups compared to controls (all P < 0.05). The p-tau217 to NfL ratio discriminated ALS from AD with an ROC-AUC of 0.92 (95% CI 0.85-0.97) compared to p-tau217 alone at 0.65 (95% CI 0.52-0.76). No ALS clinical or longitudinal association survived correction for multiple comparisons. Elevated p-tau217 and inferred amyloid-β; positivity in ALS provide further evidence that the assay signal is not necessarily specific for AD pathology. However, the use of p-tau217 in combination with NfL provides improved discriminatory power between ALS and AD, supporting the use of plasma biomarker combinations rather than sole reliance on individual plasma biomarkers. Inferred amyloid-β; positivity in cognitively impaired CVD may indicate AD and/or cerebral amyloid angiopathy co-pathology. Currently available plasma biomarkers should therefore be used as diagnostic complements and interpreted within clinical context rather than as standalone molecular diagnoses.

medRxiv
Western University (CA), Montreal Neurological Institute and Hospital (CA), St. Michael's Hospital (CA), Lawson Health Research Institute (CA), Gladstone Institutes (US), Sunnybrook Health Science Centre (CA), University Health Network (CA), Centre for Addiction and Mental Health (CA), University of Ottawa (CA), University of Alberta (CA), University of Calgary (CA), University of Toronto (CA), Queen's University (CA), Sahlgrenska University Hospital (SE), Baycrest Hospital (CA), Parkwood Institute (CA), Hôpital du Sacré-Cœur de Montréal (CA), Bruyère (CA), Vassar Brothers Medical Center (US), St Joseph's Health Care (CA), Canadian Sleep & Circadian Network (CA), Sunnybrook Hospital (CA), Ottawa Hospital Research Institute (CA), Krembil Brain Institute (CA), Sunnybrook Research Institute (CA), uOttawa Brain and Mind Research Institute (CA), Robarts Research Institute (CA), Nuvance Health (US), Lawson Research Institute (CA), Baycrest Academy for Research and Education (CA), Hotchkiss Brain Institute (CA), Rotman Research Institute (CA), Keenan Research Centre for Biomedical Science (CA), McGill University (CA), Université de Montréal (CA), University of Gothenburg (SE), McMaster University (CA)
Dementia and Cognitive Impairment Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon